RegenTherapy

RegenTherapy is a clinical-stage biotechnology company focused on the development and commercialization of regenerative medicine therapies using adipose-derived stromal vascular fraction (SVF). The company utilizes a proprietary process to isolate SVF, which contains a high concentration of mesenchymal stem cells, endothelial progenitor cells, and growth factors. RegenTherapy is currently advancing several lead programs through Phase 2 clinical trials for high-impact indications, including osteoarthritis, chronic obstructive pulmonary disease (COPD), and type 2 diabetes. By leveraging the body's own regenerative potential, the company aims to provide minimally invasive alternatives to traditional surgical interventions and improve long-term patient outcomes.